Kernal Bio
June 17, 2025
Company Presentation
Immunology
153C
Kernal Bio is VC-backed biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming inside the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, USA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA.
Company HQ City:
Cambridge
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
KR-335
CEO
Yusuf Erkul, MD, MBA
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
4
What is your next catalyst (value inflection) update?
Dec 2025
Website
https://kernalbio.com/
)
)
){kind=logo}
){kind=logo}
){kind=logo}